Shares of Genmab A/S (OTCMKTS:GNMSF - Get Free Report) gapped up before the market opened on Wednesday . The stock had previously closed at $198.51, but opened at $215.00. Genmab A/S shares last traded at $215.00, with a volume of 158 shares.
Genmab A/S Stock Performance
The stock has a market capitalization of $14.20 billion, a price-to-earnings ratio of 12.19 and a beta of 0.91. The firm's fifty day simple moving average is $208.14 and its 200 day simple moving average is $205.77.
Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $3.05 EPS for the quarter, topping the consensus estimate of $1.88 by $1.17. The firm had revenue of $765.14 million for the quarter, compared to the consensus estimate of $761.09 million. Genmab A/S had a net margin of 35.11% and a return on equity of 19.23%.
Genmab A/S Company Profile
(
Get Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Recommended Stories
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
